Sorin Group Launches New Implantable Device Leads in U.S. Market
Sorin Group announced U.S. Food and Drug Administration (FDA) approval and commercial launch in May 2012 for a full portfolio of pacing, defibrillation and left ventricular leads. Designed for effective electrical performance and durability, each of the three lead series – Tilda pacing leads, Vigila defibrillation leads and Celerity left ventricular leads – include multiple sizes and features to enable physicians to match their implant preferences with individual patient needs.
In addition to a flexible silicone lead body, steroid-eluting tips that reduce inflammation, and iridium fractal coated electrodes with proven electrical performance, each lead family offers its own additional features:
- Tilda pacing leads include a flexible lead body and distal tip and are designed for easy implantation and predictable performance.
- Vigila defibrillation leads feature a symmetrical lead body and thick outer insulation. Convex shock coils embedded in silicone insulation are engineered to minimize tissue in-growth.
- Celerity left ventricular leads have a flexible co-radial body, and are designed to facilitate access and ensure stability in targeted pacing sites regardless of patients’ coronary venous anatomies.
For more information: www.sorin.com